Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2V617F mutation is common in old patients with polycythemia vera and essential thrombocythemia.

Aging clinical and experimental research - 1 Feb 2011

Randi Maria Luigia, Ruzzon Elisabetta, Tezza Fabiana, Scapin Margherita, Duner Elena, Scandellari Raffaella, Fabris Fabrizio

Abstract excerpt

BACKGROUND: JAK2V617F mutation occurs in 90% of polycythemia vera (PV) and in 50% of essential thrombocythemia (ET) patients. MATERIALS AND METHODS: 253 consecutive patients affected by myeloproliferative disorders (MPD, 121 PV, 132 ET) were evaluated and stratified in 4 age groups: 18-39, 40-59, 60-75 and over 75 years (>75). The JAK2V617F mutation was searched and its allele burden was evaluated. RESULTS: The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Mutation

Share to Polycythemia Vera

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 21499015
DOI: 10.1007/BF03324948

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2V617F mutation is common in old patients with polycythemia vera and essential thrombocythemia.PMID 21499015Read ↗

Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burdenSemantic proximity Read ↗

A higher JAK2V617F allele burden may be a risk factor for hemorrhagic events in younger patients with polycythemia vera.Semantic proximity Read ↗

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemiaSemantic proximity Read ↗

Clinical correlates of JAK2V617F allele burden in essential thrombocythemia.Semantic proximity Read ↗

Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden.Semantic proximity Read ↗

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.Semantic proximity Read ↗

JAK2 V617F allele burden in polycythemia vera: burden of proof.Semantic proximity Read ↗

JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome.Semantic proximity Read ↗

Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia.Semantic proximity Read ↗

Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.Semantic proximity Read ↗

JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients.Semantic proximity Read ↗

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.